These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10653102)

  • 1. Value of myofibrillar protein catabolic rate in Duchenne muscular dystrophy. A study after lower limb surgery.
    Forst J; Krüger P; Forst R
    Arch Orthop Trauma Surg; 2000; 120(1-2):38-41. PubMed ID: 10653102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased myofibrillar protein catabolism in duchenne muscular dystrophy measured by 3-methylhistidine excretion in the urine.
    Mussini E; Cornelio F; Colombo L; De Ponte G; Giudici G; Cotellessa L; Marcucci F
    Muscle Nerve; 1984 Jun; 7(5):388-91. PubMed ID: 6738577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased myofibrillar protein catabolism in Duchenne muscular dystrophy measured by 3-methylhistidine excretion in the urine.
    McKeran RO; Halliday D; Purkiss P
    J Neurol Neurosurg Psychiatry; 1977 Oct; 40(10):979-81. PubMed ID: 591977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased turnover of muscle contractile proteins in Duchenne muscular dystrophy as assessed by 3-methylhistidine and creatinine excretion.
    Ballard FJ; Tomas FM; Stern LM
    Clin Sci (Lond); 1979 Apr; 56(4):347-52. PubMed ID: 477220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-methylhistidine excretion in myotonic dystrophy.
    Griggs RC; Moxley RT; Forbes GB
    Neurology; 1980 Dec; 30(12):1262-7. PubMed ID: 7192806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Content of methylhistidines in normal and pathological human skeletal muscles.
    Mussini E; Cornelio F; Dworzak F; Cotellessa L; Morandi L; Colombo L; De Ponte G; Marcucci F
    Muscle Nerve; 1983; 6(6):423-9. PubMed ID: 6621612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased rates of myofibrillar protein breakdown in muscle-wasting diseases.
    Warnes DM; Tomas FM; Ballard FJ
    Muscle Nerve; 1981; 4(1):62-6. PubMed ID: 7231447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown.
    Elia M; Carter A; Bacon S; Winearls CG; Smith R
    Br Med J (Clin Res Ed); 1981 Jan; 282(6261):351-4. PubMed ID: 6780020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary 3-methylhistidine and urinary 3-methylhistidine/creatinine ratio in Duchenne-muscular dystrophy in hemizygotes and in gene-carriers.
    László A; Klujber L
    Acta Paediatr Hung; 1984; 25(4):339-41. PubMed ID: 6525307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-Methylhistidine excretion as an index of myofibrillar protein catabolism in neuromuscular disease.
    McKeran RO; Halliday D; Purkiss P; Royston P
    J Neurol Neurosurg Psychiatry; 1979 Jun; 42(6):536-41. PubMed ID: 469561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myofibrillar protein catabolic rates in cirrhotic patients with and without muscle wasting.
    Zoli M; Marchesini G; Dondi C; Bianchi GP; Pisi E
    Clin Sci (Lond); 1982 Jun; 62(6):683-6. PubMed ID: 7083759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Branched-chain ketoacids reduce muscle protein degradation in Duchenne muscular dystrophy.
    Stewart PM; Walser M; Drachman DB
    Muscle Nerve; 1982 Mar; 5(3):197-201. PubMed ID: 7088016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myofibrillar protein degradation in the chicken. 3-Methylhistidine release in vivo and in vitro in normal and genetically muscular-dystrophic chickens.
    Hillgartner FB; Williams AS; Flanders JA; Morin D; Hansen RJ
    Biochem J; 1981 May; 196(2):591-601. PubMed ID: 7316997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-dependent changes in the rate of myofibrillar protein degradation in humans as assessed by 3-methylhistidine and creatinine excretion.
    Tomas FM; Ballard FJ; Pope LM
    Clin Sci (Lond); 1979 Apr; 56(4):341-6. PubMed ID: 477219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Scoliosis and hip flexion contracture in Duchenne muscular dystrophy].
    Fürderer S; Hopf C; Zöllner J; Eysel P
    Z Orthop Ihre Grenzgeb; 2000; 138(2):131-5. PubMed ID: 10820878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gait deviations in Duchenne muscular dystrophy-Part 2. Statistical non-parametric mapping to analyze gait deviations in children with Duchenne muscular dystrophy.
    Goudriaan M; Van den Hauwe M; Simon-Martinez C; Huenaerts C; Molenaers G; Goemans N; Desloovere K
    Gait Posture; 2018 Jun; 63():159-164. PubMed ID: 29751322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical treatment of Duchenne muscular dystrophy patients in Germany: the present situation.
    Forst J; Forst R
    Acta Myol; 2012 May; 31(1):21-3. PubMed ID: 22655513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary prostaglandin metabolites as Duchenne muscular dystrophy progression markers.
    Takeshita E; Komaki H; Tachimori H; Miyoshi K; Yamamiya I; Shimizu-Motohashi Y; Ishiyama A; Saito T; Nakagawa E; Sugai K; Sasaki M
    Brain Dev; 2018 Nov; 40(10):918-925. PubMed ID: 30006121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant hyperthermia of Duchenne muscular dystrophy: application of clinical grading scale and caffeine contracture of skinned muscle fibers].
    Takagi A
    Rinsho Shinkeigaku; 2000 May; 40(5):423-7. PubMed ID: 11002722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.